Spear Bio has developed a homogeneous immunoassay platform utilizing patented SPEAR technology to achieve ultra-sensitive detection of trace biomarkers at the single-molecule level, requiring as little as 1 µL of sample volume. This technology addresses the challenge of non-specific noise in biomarker assays, enabling precise analysis across a range of diseases without the need for high-affinity antibodies.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BTFounders
Product
Problem
Current immunoassay platforms often struggle with non-specific noise, hindering the accurate detection of low-abundance biomarkers, and typically require large sample volumes. This limits precise analysis, especially in early-stage disease diagnostics and monitoring where sample availability may be scarce.
Solution
Spear Bio has developed the SPEAR (Successive Proximity Extension Amplification Reaction) technology, a homogeneous immunoassay platform designed for ultra-sensitive biomarker detection. The platform minimizes non-specific noise through a two-factor authentication process, ensuring signal originates from genuine proximity binding before amplification using standard qPCR. This approach enables the detection of trace biomarkers at the single-molecule level, even with sample volumes as small as 1 µL. The wash-free workflow and flexible platform broadens the diversity of ultra-sensitive biomarker assays across a range of diseases.
Target Audience
The primary users are academic and clinical researchers, as well as practitioners focused on early-stage disease diagnostics and monitoring, particularly in neurology, infectious disease, and immunology.
Features
- Patented SPEAR technology employing two-factor authentication for signal accuracy
- Homogeneous assay format enabling ultra-sensitivity without requiring high-affinity antibodies or wash steps
- Detection of trace biomarkers in the single-molecule range
- Requires only 1 µL or less of sample volume
- Broad application across neurology, infectious disease, and immunology biomarker research
- Quality Management System certified to ISO 13485:2016